MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 463682 | Name: MSA-2
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MSA 2 is a non-nucleotide STING agonist. It exhibits antitumor activity and stimulates interferon-β secretion in tumors. MSA 2 induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models. It is also orally bioavailable.

Chemical Structure

MSA-2
MSA-2
CAS#129425-81-6

Theoretical Analysis

MedKoo Cat#: 463682

Name: MSA-2

CAS#: 129425-81-6

Chemical Formula: C14H14O5S

Exact Mass: 294.0562

Molecular Weight: 294.32

Elemental Analysis: C, 57.13; H, 4.79; O, 27.18; S, 10.89

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 2,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MSA 2; MSA2; MSA-2;
IUPAC/Chemical Name
4-(5,6-dimethoxybenzo[b]thiophen-2-yl)-4-oxobutanoic acid
InChi Key
APCLRHPWFCQIMG-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H14O5S/c1-18-10-5-8-6-13(9(15)3-4-14(16)17)20-12(8)7-11(10)19-2/h5-7H,3-4H2,1-2H3,(H,16,17)
SMILES Code
COC1=CC2=C(C=C(S2)C(CCC(O)=O)=O)C=C1OC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively.
In vitro activity:
MSA-2 in solution exists as monomers and noncovalent dimers in an equilibrium that strongly favors monomers; MSA-2 monomers cannot bind STING, whereas the noncovalent MSA-2 dimers bind STING with nanomolar affinity. MSA-2 exhibits substantially higher cellular potency in an acidified tumor microenvironment than normal tissue, owing to increased cellular entry and retention combined with the inherently steep MSA-2 concentration dependence of STING occupancy. Reference: Science. 2020 Aug 21;369(6506):eaba6098. https://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=32820094
In vivo activity:
MSA-2 is orally available, manifesting similar oral and subcutaneous exposure in mice. In tumor-bearing mice, MSA-2 induced elevations of interferon-b in plasma and tumors by both routes of administration. Well-tolerated regimens of MSA-2 induced tumor regressions in mice bearing MC38 syngeneic tumors. In tumor models that are moderately or poorly responsive to PD-1 blockade, combinations of MSA-2 and anti-PD-1 antibody are superior in inhibiting tumor growth and prolonging survival over monotherapy. Reference: Science. 2020 Aug 21;369(6506):eaba6098. https://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=32820094
Solvent mg/mL mM
Solubility
DMSO 50.0 169.88
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 294.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
1. Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, Trotter BW, Altman MD, Buevich AV, Cash B, Cemerski S, Chang W, Chen Y, Dandliker PJ, Feng G, Haidle A, Henderson T, Jewell J, Kariv I, Knemeyer I, Kopinja J, Lacey BM, Laskey J, Lesburg CA, Liang R, Long BJ, Lu M, Ma Y, Minnihan EC, O'Donnell G, Otte R, Price L, Rakhilina L, Sauvagnat B, Sharma S, Tyagarajan S, Woo H, Wyss DF, Xu S, Bennett DJ, Addona GH. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020 Aug 21;369(6506):eaba6098. doi: 10.1126/science.aba6098. PMID: 32820094.
In vivo protocol:
1. Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, Trotter BW, Altman MD, Buevich AV, Cash B, Cemerski S, Chang W, Chen Y, Dandliker PJ, Feng G, Haidle A, Henderson T, Jewell J, Kariv I, Knemeyer I, Kopinja J, Lacey BM, Laskey J, Lesburg CA, Liang R, Long BJ, Lu M, Ma Y, Minnihan EC, O'Donnell G, Otte R, Price L, Rakhilina L, Sauvagnat B, Sharma S, Tyagarajan S, Woo H, Wyss DF, Xu S, Bennett DJ, Addona GH. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020 Aug 21;369(6506):eaba6098. doi: 10.1126/science.aba6098. PMID: 32820094.
1: Yi M, Niu M, Wu Y, Ge H, Jiao D, Zhu S, Zhang J, Yan Y, Zhou P, Chu Q, Wu K. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. J Hematol Oncol. 2022 Oct 8;15(1):142. doi: 10.1186/s13045-022-01363-8. PMID: 36209176; PMCID: PMC9548169. 2: Yang J, Luo Z, Ma J, Wang Y, Cheng N. A next-generation STING agonist MSA-2: From mechanism to application. J Control Release. 2024 Jul;371:273-287. doi: 10.1016/j.jconrel.2024.05.042. Epub 2024 Jun 1. PMID: 38789087. 3: Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, Trotter BW, Altman MD, Buevich AV, Cash B, Cemerski S, Chang W, Chen Y, Dandliker PJ, Feng G, Haidle A, Henderson T, Jewell J, Kariv I, Knemeyer I, Kopinja J, Lacey BM, Laskey J, Lesburg CA, Liang R, Long BJ, Lu M, Ma Y, Minnihan EC, O'Donnell G, Otte R, Price L, Rakhilina L, Sauvagnat B, Sharma S, Tyagarajan S, Woo H, Wyss DF, Xu S, Bennett DJ, Addona GH. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020 Aug 21;369(6506):eaba6098. doi: 10.1126/science.aba6098. PMID: 32820094. 4: Lin H, Zhang R, Xiang H, Lin X, Huang X, Chen J, Zhou L, Zhang Z, Li Y. A Non-Nucleotide STING Agonist MSA-2 Synergized with Manganese in Enhancing STING Activation to Elicit Potent Anti-RNA Virus Activity in the Cells. Viruses. 2023 Oct 24;15(11):2138. doi: 10.3390/v15112138. PMID: 38005816; PMCID: PMC10675287. 5: Cai Y, He T, Yang T, Li Y, Yi L, Li W, Zhou P. Reproductive safety of STING agonists MSA-2 and manganese-MSA-2. Toxicol Res (Camb). 2024 Oct 13;13(5):tfae172. doi: 10.1093/toxres/tfae172. PMID: 39403122; PMCID: PMC11471313. 6: Liu J, Huang X, Ding J. Identification of MSA-2: An oral antitumor non- nucleotide STING agonist. Signal Transduct Target Ther. 2021 Jan 12;6(1):18. doi: 10.1038/s41392-020-00459-2. PMID: 33436539; PMCID: PMC7804957. 7: Wang M, Cai Y, He T, Zhang Y, Yi L, Li W, Zhou P. Antitumor Effect of Platinum-Modified STING Agonist MSA-2. ACS Omega. 2024 Jan 3;9(2):2650-2656. doi: 10.1021/acsomega.3c07498. PMID: 38250379; PMCID: PMC10795137. 8: Chen X, Meng F, Xu Y, Li T, Chen X, Wang H. Chemically programmed STING- activating nano-liposomal vesicles improve anticancer immunity. Nat Commun. 2023 Jul 31;14(1):4584. doi: 10.1038/s41467-023-40312-y. PMID: 37524727; PMCID: PMC10390568. 9: Chen F, Li T, Zhang H, Saeed M, Liu X, Huang L, Wang X, Gao J, Hou B, Lai Y, Ding C, Xu Z, Xie Z, Luo M, Yu H. Acid-Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer. Adv Mater. 2023 Mar;35(10):e2209910. doi: 10.1002/adma.202209910. Epub 2023 Jan 10. PMID: 36576344. 10: Schleyer K, Halabi EA, Weissleder R. γ-Butyrolactone Derivatives of MSA-2 are STING Prodrugs. ChemMedChem. 2024 Oct 1;19(19):e202400416. doi: 10.1002/cmdc.202400416. Epub 2024 Aug 5. PMID: 38887174.
Lu Z, Chen J, Yu P, Atherton MJ, Gui J, Tomar VS, Middleton JD, Sullivan NT, Singhal S, George SS, Woolfork AG, Weljie AM, Hai T, Eruslanov EB, Fuchs SY. Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer. Nat Commun. 2022 Nov 4;13(1):6623. doi: 10.1038/s41467-022-34428-w. PMID: 36333297; PMCID: PMC9636202.